At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for High Grade Meningioma. Active but no longer recruiting, targeting 26 participants across 2 sites.
Signals
Detailed Summary
This research study is studying a drug as a possible treatment for High Grade Meningioma. The drug involved in this study is an immunotherapy drug called pembrolizumab
Study Details
Timeline
Arms & Interventions
* Pembrolizumab will be administered every 3 weeks * Pembrolizumab will be administered through IV infusion
Interventions
pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells